Business
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide is showing apparent superiority to DehydraTECH-semaglutideSelect DehydraTECH-CBD formulations are showing apparent superiority to
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"DehydraTECH-liraglutide is showing apparent superiority to DehydraTECH-semaglutideSelect DehydraTECH-CBD formulations are showing apparent superiority to DehydraTECH-GLP-1 at 4 and 8 weeks KELOWNA, BC / ACCESSWIRE / August 21, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms announces that it has received 4-week and 8-week blood glucose results from ongoing animal study WEIGHT-A24-1 (the \"Study\").DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B) were the top performers in the Study at day 56, with blood sugar level reductions of 2.50%, 1.90% and 1.53% respectively. This appears to support Lexaria's belief that DehydraTECH-CBD may have utility, especially if used together with a GLP-1 drug, in diabetic control. Animal testing of combination DehydraTECH-CBD with DehydraTECH-GLP-1 drugs is ongoing and in the final phases of the Study.For context, in Lexaria's diabetic animal study DIAB-A22-1 reported on March 2, 2023, the obese control group of animals that received no treatment experienced 16.7% blood sugar concentration increases, relative to baseline by day 56 of that study. In the current Study, each of the 8 active groups of animals either experienced a smaller increase, or an actual decrease in blood sugar level relative to baseline as compared to the obese control group in the previous study. Interestingly, none of the animals receiving semaglutide experienced actual decreases by day 56 although some decreases were observed at day 28.Blood Sugar Levels (nmol/L)DehydraTECH GroupsDay 7 BaselineDay 28% Change to Day 28Day 56% Change to Day 56A: CBD127.426.2-4.3126.9-1.90B: CBD228.429.24.0526.6-1.53C: CBD326.424.9-5.9927.12.46D: CBD424.627.913.1626.88.94E: Rybelsus1w/SNAC26.425.5-3.6026.81.33F: Rybelsus2w/SNAC24.926.87.7026.45.96G: SemaglutideNo SNAC26.325.9-1.5227.85.54H: LiraglutideNo SNAC26.425.8-2.0825.2-2.50Notes:Groups A through D were different DehydraTECH-CBD compositionsGroups E and F were reformulated Rybelsus DehydraTECH compositionsGroups G and H used pure GLP-1 drugs (semaglutide and liraglutide respectively)in DehydraTECH compositionsThe continued relative outperformance of DehydraTECH liraglutide is extremely interesting, in part because of Lexaria's proprietary DehydraTECH technology...